Intellia Therapeutics, Inc.

Intellia Therapeutics is a gene-editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. Intellia is focused on using this technology to treat genetically defined diseases. It's evaluating multiple gene editing approaches using in vivo and ex vivo therapies to address diseases with high unmet medical needs, including ATTR amyloidosis, hereditary angioedema, sickle cell disease, and immuno-oncology. Intellia has formed collaborations with several companies to advance its pipeline, including narrow-moat Regeneron and wide-moat Novartis.

Consensus

—

Average target

$18.69

Implied upside

—

Analysts

—

Why Is NTLA Down Today Despite FDA Priority Review Win?

Intellia Therapeutics shares declined 3.21% today despite securing positive FDA news, as the market digests the acceptance of its biologics license application for Lonvoguran Ziclumeran (Lonvo-z) with a March 10, 2027 PDUFA date. The disconnect between positive developments and price action suggests investors may be pricing in the lengthy timeline or reassessing near-term catalysts for the gene-editing platform company.

Bottom line: While Intellia's FDA Priority Review acceptance for Lonvo-z is objectively positive news for the company's gene-editing platform, today's 3.21% decline reflects market skepticism around the lengthy 18-month timeline and limited immediate revenue catalysts. Investors should monitor regulatory progress through 2027 and watch for any additional clinical data or pipeline updates that could reignite interest in this high-risk, high-reward biotech play.